Streetbeat News

Earnings

NVCR

NovoCure's stock is trading higher following the company's announcement of preliminary Q4 and full-year 2023 revenue guidance that exceeded analysts' expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 6:01 pm

TVTX

Travere Therapeutics' stock is trading higher following their preliminary Q4 and FY23 net product sales guidance from continuing operations. The company also announced that its cash reserves and marketable securities are projected to fund operations until 2028.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:59 pm

PBPB

Potbelly Corporation's stock is trading higher following the release of preliminary guidance indicating growth in same-store sales for both the fourth quarter and the full year of 2023.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:52 pm

PBPB

Potbelly Corporation anticipates preliminary FY23 same-store sales growth to be between 11.9% and 12%, indicating a positive performance trend for the company.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:51 pm

BA

DIA

IWM

QQQ

SPY

The New York Fed's December 2023 Survey of Consumer Expectations showed a significant drop in consumer inflation expectations, reaching a 2-year low. Expectations for inflation, earnings growth, and spending growth have all decreased. Despite this, the job market outlook remains positive, with a slight decrease in the perceived probability of job loss and an increase in the probability of finding a new job. Interest rate increase expectations have fallen, while stock market expectations have marginally improved. Stocks, including SPY, QQQ, and IWM, saw gains, while DIA experienced a slight dip due to a decline in Boeing Co's shares.

Portfolio Pulse from Piero Cingari

January 08, 2024 | 5:43 pm

ATEC

Alphatec Holdings' stock is trading higher following the company's announcement of preliminary Q4 and FY23 revenue guidance that exceeded expectations. Additionally, Alphatec has entered into a strategic partnership with Aclarion to further the commercialization of Nociscan.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:43 pm

BLFS

BioLife Solutions shares are trading higher following the company's issuance of preliminary Q4 and FY23 revenue guidance, indicating positive performance expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:38 pm

STAA

STAAR Surgical's stock is trading higher following the company's announcement of preliminary Q4 and FY23 net sales guidance that exceeded analysts' expectations.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:36 pm

DXCM

DexCom's stock is trading higher following the release of their preliminary Q4 and full year 2023 revenue results, along with their guidance for 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 5:32 pm

SCHW

Options trading activity for Charles Schwab (NYSE:SCHW) indicates a bearish sentiment among financial giants, with 55% of unusual trades being bearish. The trades suggest a target price range of $57.5 to $80.0 over the next three months. The largest options spotted were bullish call sweeps with expiration dates in 2024. Charles Schwab is a major player in brokerage and wealth management with over $7 trillion in client assets. The stock is slightly up with potential overbought signals and an earnings announcement due in 14 days. Analyst ratings vary, with an average target price of $76.67, but recent downgrades from Goldman Sachs and TD Cowen suggest caution.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 5:31 pm